Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04880161 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID)
A Phase 1 study, sponsored by Ampio Pharmaceuticals..
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT04880161 is a Phase 1 study that has completed, run by Ampio Pharmaceuticals.. The registered enrollment target is 32 participants.
The verdict
NCT04880161, a Phase 1 study, has completed, sponsored by Ampio Pharmaceuticals..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a phase I study to evaluate the safety and efficacy of inhaled Ampion on patients with prolonged respiratory symptoms due to COVID-19 (Long COVID).
Interventions
- OTHER Placebo
- BIOLOGICAL Ampion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2021-07-26 |
| Est. Completion | 2022-02-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04880161
The ClinicalTrials.gov registry entry for NCT04880161 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ampio Pharmaceuticals., which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04880161 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04880161 about?
NCT04880161 is a clinical study titled "A Study to Evaluate Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID)". This is a phase I study to evaluate the safety and efficacy of inhaled Ampion on patients with prolonged respiratory symptoms due to COVID-19 (Long COVID).
What is the current status of trial NCT04880161?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2021-07-26. Estimated completion is 2022-02-21.
What interventions are being tested in trial NCT04880161?
The interventions under investigation include: Placebo (OTHER), Ampion (BIOLOGICAL).
Who is sponsoring clinical trial NCT04880161?
This trial is sponsored by Ampio Pharmaceuticals., which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.